Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
ZLAB(NASDAQ:ZLAB) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. “Today’s approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China,” said Andrew Zhu, Chief Commercial Of
Zai Lab Announces Participation in Investor Conferences in September 2025
ZLABSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2025: Cantor Global Healthcare Conference Presentation: Thursday, September 4, 2025, 10:20 a.m. ET Location: New York, NY Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Tuesday, September 9, 2025, 2:35 p.m. ET Location: New York, NY Live webcasts wi
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
ZLABSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunit
Zai Lab Establishes Oncology Scientific Advisory Board
ZLABSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company’s robust oncology products and pipeline, including multiple internally developed investigational therapies. “We are honored to bring together this esteemed group of oncology leaders who will support our cont
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
ZLABSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering a pivotal period – defined by innovation, scale and strong execution,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and opera
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
ZLABSHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotl
Zai Lab Limited Announced That Updated Data From An Ongoing, Global Phase 1A/1B Clinical Trial (NCT06179069) Evaluating Zocilurtatug Pelitecan, Or Zl-1310, The Company's Potential First-in-class, Delta-like Ligand (DLL3) Antibody-drug Conjugate (ADC) For
ZLABZai Lab Receives FDA Fast Track Designation For ZL-1310
ZLABCORRECTION: Zai Lab Q1 EPADS $(0.45) Beats $(0.55) Estimate, Sales $106.49M Miss $116.76M Estimate
ZLABZai Lab Affirms FY2025 Sales Guidance of $560.00M-$590.00M vs $564.97M Est
ZLABZai Lab Q1 EPS $(0.04) Beats $(0.55) Estimate, Sales $106.49M Miss $116.76M Estimate
ZLABZai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
ZLABChina's National Medical Products Administration Accepts Zai Lab's New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors
ZLABCantor Fitzgerald Reiterates Overweight on Zai Labto Overweight
ZLABZai Lab Announced That New Data From Internally Developed, Next-generation Oncology Candidates Will Be Presented During Poster Sessions At The Upcoming American Association For Cancer Research (Aacr) Annual Meeting 2025 Taking Place April 25-30, 2025 In C
ZLABJP Morgan Maintains Overweight on Zai Lab, Raises Price Target to $51
ZLABReported Earlier, Zai Lab's BLA For TIVDAK Accepted In China For Recurrent Or Metastatic Cervical Cancer
ZLABScotiabank Initiates Coverage On Zai Lab with Sector Outperform Rating, Announces Price Target of $55
ZLABB of A Securities Downgrades Zai Lab to Neutral, Raises Price Target to $36.1
ZLABZai Lab Expects 2025 Revenue In The Range Of $560M-$590M Vs. $567.84M Estimate
ZLABZai Lab Q4 2024 GAAP EPADS $(0.80) Up From $(0.98) YoY, Sales $109.07M Beat $108.17M Estimate
ZLABZai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 innovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer
ZLABReported Earlier, Zai Lab Expands Oncology Pipeline With MediLink Collaboration For Novel LRRC15 ADC ZL-6201
ZLABWhy Zai Lab (ZLAB) Stock Is Trading Higher
ZLABZai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.
Reported Earlier, Zai Lab Prices 7.8M American Depositary Shares At $25.50/ADS In $200M Public Offering
ZLABZai Lab Has Dosed The First Patient In The Phase 2 Trial Of ZL-1102 For Chronic Plaque Psoriasis
ZLAB